^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
multiplexed MAGEA1/PRAME TCR-T cell therapy
i
Other names: multiplexed MAGEA1/PRAME TCR-T cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TSCan Therap
Drug class:
TCR modulator, PRAME inhibitor, MAGE-A1 modulator
Related drugs:
2years
Multiplexed TCR-T cell therapy targeting MAGEA1 and PRAME enhances the activity of adoptive T cell therapy in pre-clinical models (SITC 2022)
Notably, when treated with multiplexed MAGEA1/PRAME TCR-T, the mice achieved longer lasting tumor control compared to TCR-T targeting a single antigen. Conclusions These findings support the hypothesis that multiplexed TCR-T mimics the natural oligoclonal T-cell response to cancer and has the potential to overcome antigen heterogeneity, which may contribute to the observed lack of durability in monotherapy TCR-T clinical trials.
Preclinical
|
HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAGEA1 (MAGE Family Member A1)
|
HLA-A*02
|
multiplexed MAGEA1/PRAME TCR-T cell therapy
Share via
